LGND news

Ligand reported a 51% year-over-year increase in royalty revenue to $70.3 million and raised full-year Adjusted Diluted EPS guidance to $9.50 to $9.75. The results reflect performance from key assets like Filspari and the XOMA acquisition.

Ligand Pharmaceuticals agreed to finance two clinical-stage cell therapy candidates with up to $47 million, securing a royalty potential mid single-digit to low double-digit royalties on global sales.

Ligand agreed to acquire a 100% royalty interest in Santen's myopia drug Ryjunea in Europe and the Middle East for $23 million upfront and will receive tiered royalties on net sales.

Ligand Pharmaceuticals completed the acquisition of XOMA Royalty for ~$739 million, expanding its portfolio to over 200 royalty assets. The deal is expected to be immediately accretive and add exposure to major commercial products.

Ligand Pharmaceuticals entered into a fourth amendment to its credit agreement with Citibank as administrative agent, consenting to the issuance of up to $700 million in unsecured convertible notes subject to leverage ratio compliance. The amendment provides financing flexibility while maintaining d…